Company Description
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria.
It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program.
The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020.
Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 385 |
| CEO | Eric Dube |
Contact Details
Address: 3611 Valley Centre Drive, Suite 300 San Diego, California 92130 United States | |
| Phone | 888 969 7879 |
| Website | travere.com |
Stock Details
| Ticker Symbol | TVTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001438533 |
| CUSIP Number | 89422G107 |
| ISIN Number | US89422G1076 |
| Employer ID | 26-2383102 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric M. Dube Ph.D. | President, Chief Executive Officer and Director |
| Christopher Cline C.F.A. | Chief Financial Officer |
| Dr. William E. Rote Ph.D. | Chief Research Officer |
| Peter Heerma | Chief Commercial Officer |
| Dr. Jula Inrig M.D. | Chief Medical Officer |
| Sandra Calvin | SVice President, Corporate Controller and Chief Accounting Officer |
| Nivi Nehra | Vice President of Corporate Communications and Investor Relations |
| Elizabeth E. Reed J.D. | Chief Legal Officer, General Counsel and Secretary |
| Angela Giannantonio | Chief People Officer |
| Casey Logan | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 15, 2025 | SCHEDULE 13G/A | Filing |
| Aug 7, 2025 | SCHEDULE 13G/A | Filing |
| Aug 6, 2025 | 10-Q | Quarterly Report |
| Aug 6, 2025 | 8-K | Current Report |
| Jul 29, 2025 | SCHEDULE 13G/A | Filing |
| Jun 17, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 16, 2025 | 8-K | Current Report |
| May 15, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |